Jacinta Serpa

Artigos de 2015 a 2021:

• Cysteine Boosts Fitness Under Hypoxia-Mimicked Conditions in Ovarian Cancer by Metabolic Reprogramming. Front Cell Dev Biol. 2021. doi: 10.3389/fcell.2021.722412. - Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis. Front Oncol. 2021. doi: 10.3389/fonc.2021.656851.
• The activation of endothelial cells relies on a ferroptosis-like mechanism: novel perspectives in management of angiogenesis and cancer therapy. Front. Oncol., 2021. doi:10.3389/fonc.2021.656229.
• Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int. J. Mol. Sci. 2021; doi: 10.3390/ijms22073765 - Cysteine metabolic circuitries: druggable targets in cancer. Br J Cancer. 2021. doi: 10.1038/s41416-020-01156-1.
• Cysteine as a Carbon Source, a Hot Spot in Cancer Cells Survival. Front Oncol. 2020. doi: 10.3389/fonc.2020.00947. - Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas. Biomolecules. 2020. doi: 10.3390/biom10101370. 
• Cysteine Aminotransferase (CAT): A Pivotal Sponsor in Metabolic Remodeling and an Ally of 3-Mercaptopyruvate Sulfurtransferase (MST) in Cancer. Molecules. 2020. doi: 10.3390/molecules25173984.
• Revisiting lactate dynamics in cancer-a metabolic expertise or an alternative attempt to survive? J Mol Med (Berl). 2020. doi: 10.1007/s00109-020-01965-0.
• Polyurea Dendrimer Folate-Targeted Nanodelivery of l-Buthionine sulfoximine as a Tool to Tackle Ovarian Cancer Chemoresistance. Antioxidants (Basel). 2020. doi: 10.3390/antiox9020133. - Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis. Cells. 2020. doi: 10.3390/cells9010107.
• Unraveling FATP1, regulated by ER-b as a targeted breast cancer innovative therapy, Scientific reports. 2019. doi: 10.1038/s41598-019-50531-3. - Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation. Nutrients. 2019. doi: 10.3390/nu11102523.
• Glutathione in Ovarian Cancer: A Double-Edged Sword. International Journal of Molecular Science 2018. doi: 10.3390/ijms19071882. - Acetylation drives hepatocyte nuclear factor 1ß stability by blocking proteasome-mediated degradation. Journal of Cellular Biochemistry. 2018. doi: 10.1002/jcb.28209
• Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. Scientific Reports. 2018. doi: 10.1038/s41598-018-27753-y.
• Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer. BMC Evololutionary Biology 2018. doi: 10.1186/s12862-018-1214-1.
• Cysteine oxidative dynamics underlies hypertension and kidney dysfunction induced by chronic intermittent hypoxia. Adv Exp Med Biol. 2018. doi: 10.1007/978-3-319-91137-3_10 - Cooperation of cancer and normal cells is pivotal in cancer metabolic fitness. Tumor Biology, 2018. doi: 10.1177/1010428318756203.
• Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells. Oncotarget, 2017, doi: 10.18632/oncotarget.20294
• Breast cancer metabolic cross-talk: Fibroblasts are hubs and breast cancer cells are gatherers of lipids. Molecular and Cellular Endocrinology. 2017. doi:10.1016/j.mce.2017.01.031. 3. 
• STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. Tumor Biology 2016; DOI 10.1007/s13277-015-4385-z
• HNF1ß drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). Tumor Biology 2016; DOI 10.1007/s13277-015-4290-5

Ciência ID: 2610-7C0D-38F2

ORCID iD: 0000-0002-1548-5907